Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

SAN FRANCISCO, July 16 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed a private placement of shares of its common stock and warrants to purchase additional common stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer acted as the exclusive placement agent for the transaction.

"We are extremely pleased to have the completed this financing," said Joshua Kazam, Chief Executive Officer, "which we believe will provide us with sufficient capital to complete our Phase 2 clinical study of CD-NP in acute heart failure patients with mild to moderate renal insufficiency."

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas o
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 29, 2014 Global polyvinyl ... the world economic crisis during 2008-2009, especially in North ... recovered and currently is keeping to a growing trend. ... volume is utilized in the construction segment. In 2013, ... pipes, profiles, tubing, sheets and rigid film. Moreover, the ...
(Date:10/30/2014)... James Sherley says he has been working towards ASCTC ... his days as a principal investigator at the Fox Chase ... Sherley founded the ASCTC as a new Boston biotech start-up ... developed in Sherley’s research over the years since FCCC, first ... and more recently as a senior scientist at the now ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/27/2014)... North Carolina (PRWEB) October 27, 2014 ... invited earlier this month to sit down with Bryan Hamilton, ... from RPG Solutions to discuss talent in the Research Triangle ... topics that were highlighted at the roundtable include ... the Triangle, the significance of work/life balance and the unique ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... Family of, Tissue Dissection Tools, Which Have Been Used ... ... Calif., Oct. 28 PEAK Surgical, Inc., a,medical device company ... proprietary technology, has introduced two extensions to its,PEAK PlasmaBlade(TM) family ...
... Senomyx,s Discovery of a Promising New Flavor Ingredient Achieves ... Collaboration ... (Nasdaq: SNMX ), a leading company focused on using proprietary,technologies ... ingredient supply industries, announced today that it has,received a payment from ...
... to Advance P-552, DURHAM, N.C., Oct. 28 ... they have entered into an agreement to,co-develop Parion,s proprietary ... mouth associated with primary Sjogren,s syndrome., Under the ... P-552. Kainos will provide funding to help advance the,program ...
Cached Biology Technology:PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 2PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 3SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 2Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 3
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
(Date:10/29/2014)... 2014 – Ghrelin is a hormone released by the ... is commonly viewed as a psychoactive substance that primarily ... caloric food. , This knowledge, combined with findings ... ghrelin has the potential to stimulate alcohol craving. , ... humans and found that, as they had anticipated, alcohol ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... found a critical piece in the evolutionary puzzle that ... ago. The team, from the School of Biomedical ... into more complex cells and found this crucial step ... thought. Team leader and ARC Federation Fellow ...
... The Translational Genomics Research Institute (TGen) today announced the ... the Van Andel Research Institute (VARI) that will maximize ... TGen expects the agreement to create a robust basic-science-to-translational ... for patient benefit. "We are ...
... are especially reactive to stress are more vulnerable to ... their peers. But a new longitudinal study suggests that ... well when they,re raised in supportive environments. The ... the University of California, San Francisco, and the University ...
Cached Biology News:An answer to another of life's big questions 2TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3High sensitivity to stress isn't always bad for children 2
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
... Tyrosine Hydroxylase (Ser40) Polyclonal Antibody ... against synthetic phosphopeptide corresponding to ... phospho-Ser40 of rat Tyrosine Hydroxylase ... by sequential chromatography on phospho- ...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Biotin anti-human CD164...
Biology Products: